LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea [Yahoo! Finance]
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
A Look at LivaNova's (LIVN) Valuation Following Its Recent 20% Share Price Surge [Yahoo! Finance]
LivaNova (NASDAQ:LIVN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.